The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
(1) Background: Chronic kidney disease (CKD) is extremely common against the backdrop of type 2 diabetes (T2D), accounting for nearly 30–40% of cases. The conventional management strategy relie predominantly on metabolic control and the renin–angiotensin–aldosterone system (RAAS) blockage. In the la...
Main Authors: | Samit Ghosal, Shamita Ghosal, Anuradha Ghosal |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/20/6462 |
Similar Items
-
Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
by: Adrian Post, et al.
Published: (2020-05-01) -
Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01) -
Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
by: Samit Ghosal, et al.
Published: (2023-07-01) -
Association between rapid renal function deterioration and cancer mortality in the elderly: A retrospective cohort study
by: I‐Ching Kuo, et al.
Published: (2023-04-01) -
A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
by: Giovanna Capolongo, et al.
Published: (2022-04-01)